Reviva Pharmaceuticals Aims for Q2 2026 NDA Submission for Schizophrenia Treatment
ByAinvest
Friday, Nov 14, 2025 5:57 pm ET1min read
RVPH--
Reviva Pharmaceuticals is advancing its schizophrenia treatment, brilaroxazine, towards regulatory approval with a potential NDA submission by Q2 2026. The company faces significant financial challenges, with negative earnings growth and a low Piotroski F-Score. Despite these challenges, Reviva has a robust clinical and non-clinical data package and hopes that brilaroxazine's unique clinical benefits will enhance treatment outcomes for schizophrenia patients globally.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet